



NEW CLINICAL APPROACHES FOR ALS, CIDP, AND MG:

Improving Outcomes through Optimal Diagnosis
and Emerging Targeted Therapies

Suggested Readings List

Amyotrophic Lateral Sclerosis

- Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. *N Engl J Med.* 2017;377(2):162-172. doi: 10.1056/NEJMra1603471
- Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. *Nat Rev Neurol.* 2014;10(11):661-70. doi: 10.1038/nrneurol.2014.184
- Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. *Clin Neurophysiol.* 2020;131(8):1975-1978. doi: 10.1016/j.clinph.2020.04.005
- Jiang J, Wang Y, Deng M. New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. *Front Pharmacol.* 2022;13:1054006. doi: 10.3389/fphar.2022.1054006
- McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. *Acta Neuropathol.* 2019;137(5):715-730. doi: 10.1007/s00401-018-1933-9
- Mifflin L, Hu Z, Dufort C, et al. A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis. *Proc Natl Acad Sci USA.* 2021;118(13):e2025102118. doi: 10.1073/pnas.2025102118
- Eastenson A, Hincelin-Mery A, Lewanczyk P, et al. First-in-human studies of safety, tolerability, pharmacokinetics, and pharmacodynamics of SAR443820, a centrally penetrant RIPK1 inhibitor in healthy participants. *Muscle & Nerve.* 2022;66(Suppl):abst 105. doi: 10.1002/mus.27729
- Boros BD, Schoch KM, Kreple et al. Antisense Oligonucleotides for the Study and Treatment of ALS. *Neurotherapeutics.* 2022;19(4):1145-1158. doi:10.1007/s13311-022-01247-2
- Miller TM, Cudkowicz ME, Genge A, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. *N Engl J Med.* 2022;387(12):1099-1110. doi:10.1056/nejmoa2204705
- Beers DR, Henkel JS, Zhao W, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. *Brain.* 2011;134(Pt 5):1293-314. doi: 10.1093/brain/awr074
- Thonhoff JR, Berry JD, Macklin EA, et al. Combined regulatory T-lymphocyte and IL-2 treatment is safe, tolerable, and biologically active for 1 year in persons with amyotrophic lateral sclerosis. *Neurol Neuroimmunol Neuroinflamm.* 2022;9(6):e20019. doi:10.1212/NXI.0000000200019

Chronic Inflammatory Demyelinating Polyneuropathy

- Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. *J Peripher Nerv Syst.* 2021;26(3):242-268. doi: 10.1111/jns.12455
- Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. *J Neurol Neurosurg Psychiatry.* 2019;90(9):981-987.
- Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. *J Neurol Neurosurg Psychiatry.* 2019;90(2):125-132. doi: 10.1136/jnnp-2018-318714.
- Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. *Neurology.* 2015;85(6):498-504. doi: 10.1212/WNL.0000000000001833
- Allen JA, Ney J, Lewis RA. Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. *Muscle Nerve.* 2018;57(4):542-549. doi: 10.1002/mus.25997
- Querol LA, Hartung HP, Lewis RA, et al. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. *Neurotherapeutics.* 2022;19(3):864-873. doi: 10.1007/s13311-022-01221-y
- Rumsey J, Lorance C, Jackson M, et al. CIDP patient serum triggers complement activation and functional deficits in motoneurons blocked by anti-C1s therapeutic. *J Peripheral Nervous System.* 2021;26:3
- Chow T, Shamszad P, Vinnard C, et al. First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor. *Clin Transl Sci.* 2023;16(4):673-685. doi: 10.1111/cts.13481
- Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. *Ther Adv Neurol Disord.* 2021;14:175628642199738. doi:10.1177/1756286421997381
- Ulrichs P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. *J Clin Invest.* 2018;128(10):4372-4386. doi: 10.1172/JCI97911
- Hu J, Sun C, Lu J, Zhao C, Lin J. Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. *J Neurol.* 2022;269(3):1250-1263. doi: 10.1007/s00415-021-10646-y

Myasthenia Gravis

- Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. *Nat Rev Dis Primers.* 2019;5(1):30. doi: 10.1038/s41572-019-0079-y
- Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. *Muscle Nerve.* 2007;37(2):141-149. doi:10.1002/mus.20950
- Tomschik M, Hilger E, Rath J, et al. Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. *Neurology.* 2020;95(10):e1426-e1436. doi: 10.1212/WNL.00000000000010209
- Dresser L, Wlodarski R, Rezaian K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. *JCM.* 2021;10(11):2235. doi:10.3390/jcm10112235
- Lazaridis K, Tzartos SJ. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. *Front Immunol.* 2020 Feb 14;11:212. doi: 10.3389/fimmu.2020.00212
- Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. *Ann NY Acad Sci.* 2017;1412(1):113-128. doi:10.1111/nyas.13522
- Narayanaswami P, Sanders D, Guptill J, et al. PROMISE-MG: A Multicenter Prospective Observational Comparative Effectiveness Study of Myasthenia Gravis Treatments. *Neurology.* 2022;98(18 Supplement).

- Suh J, Clarke V, Amato AA, Guidon AC. Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. *Muscle Nerve*. 2022;66(3):348-353. doi: 10.1002/mus.27656
- Vu T, Meisel A, Mantegazza R, et al. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. *NEJM Evidence*. 2022;1(5). doi:10.1056/evidoa2100066
- Howard JF, Jr., Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol*. 2021;20(7):526-36. doi: 10.1016/S1474-4422(21)00159-9
- Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. *Neurology*. 2021;98(4):e376–89. doi: 10.1212/WNL.00000000000013121
- Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. *Neurology*. 1999 Apr 22;52(7):1487-9. doi: 10.1212/wnl.52.7.1487